Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.

Adult T-cell lymphoma and leukemia may warrant up-front allogeneic transplant, according to Mary Jo Lechowicz, MD.

C. Ola Landgren, MD, PhD, discusses disparities in myeloma care access between academic and community practices and how his center works to bridge that gap.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Time to worsening of symptoms was improved with amivantamab plus chemotherapy compared with chemotherapy alone in the phase 3 PAPILLON trial.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.

Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.